BAY1436032 in Patients With Mutant IDH1(mIDH1) Advanced Acute Myeloid Leukemia (AML)
Status:
Completed
Trial end date:
2019-03-15
Target enrollment:
Participant gender:
Summary
To determine the maximum tolerated and / or recommended Phase II dose of oral mutant IDH1
(mIDH1) inhibitor BAY1436032 and to characterize its safety, tolerability, pharmacokinetics,
pharmacodynamics, and preliminary clinical efficacy in patients with mIDH1-R132X advanced
acute myeloid leukemia (AML)